OncoTherad<sup>®</sup> (MRB-CFI-1) Nanoimmunotherapy: A Promising Strategy to Treat Bacillus Calmette–Guérin-Unresponsive Non-Muscle-Invasive Bladder Cancer: Crosstalk among T-Cell CX3CR1, Immune Checkpoints, and the Toll-Like Receptor 4 Signaling Pathway

OncoTherad<sup>®</sup> (MRB-CFI-1) Nanoimmunotherapy: A Promising Strategy to Treat Bacillus Calmette–Guérin-Unresponsive Non-Muscle-Invasive Bladder Cancer: Crosstalk among T-Cell CX3CR1, Immune Checkpoints, and the Toll-Like Receptor 4 Signaling Pathway

This study assessed the safety and efficacy of OncoTherad<sup>®</sup> (MRB-CFI-1) nanoimmunotherapy for non-muscle invasive bladder cancer (NMIBC) patients unresponsive to <i>Bacillus Calmette-Guérin</i> (BCG) and explored its mechanisms of action in a bladder cancer microenv...

Full description

Bibliographic Details
Main Authors: João Carlos Cardoso Alonso, Bianca Ribeiro de Souza, Ianny Brum Reis, Gabriela Cardoso de Arruda Camargo, Gabriela de Oliveira, Maria Izabel de Barros Frazão Salmazo, Juliana Mattoso Gonçalves, José Ronaldo de Castro Roston, Paulo Henrique Ferreira Caria, André da Silva Santos, Leandro Luiz Lopes de Freitas, Athanase Billis, Nelson Durán, Wagner José Fávaro
Format: Article
Language:English
Published: MDPI AG 2023-12-01
Series:International Journal of Molecular Sciences
Subjects:
bladder cancer
immunotherapy
Oncotherad
bacillus Calmette–Guerin
nanotechnology
Online Access:https://www.mdpi.com/1422-0067/24/24/17535

Internet

https://www.mdpi.com/1422-0067/24/24/17535

Similar Items